这家位于马萨诸塞州剑桥市的公司正在开发治疗多种遗传疾病的疗法。其主要候选产品CMP-CPS-001用于治疗最常见的尿素循环疾病，目前正在早期临床试验中进行评估。Biopharmaceutical company CAMP4 Therapeutics (CAMP.US) announced on Monday that it seeks a target valuation of up to 0.283 billion USD in its initial public offering (IPO) in the USA.
According to the 36kr Financial News app, biopharmaceutical company CAMP4 Therapeutics (CAMP.US), supported by medical giant Kaiser Permanente, announced on Monday that it seeks a target valuation of up to 0.283 billion USD in its initial public offering (IPO) in the USA. CAMP4 plans to issue 5 million shares of stock priced between 14 USD and 16 USD per share, raising a maximum of 80 million USD.
As the long-awaited period of loose policy begins, the company will join the recent batch of biotechnology companies going public. Venture are also seeking to join the ranks before the uncertainty that may arise from the next month's USA presidential election.
The company based in Cambridge, Massachusetts, is developing therapies for various genetic diseases. Its main candidate product, CMP-CPS-001, is used to treat the most common urea cycle disorders and is currently being evaluated in early clinical trials.
CAMP4 is led by Josh Mandelbrehm, who previously worked at Biogen (BIIB.US) and Sanofi (SNY.US). The company will be listed on the NASDAQ under the symbol "CAMP". JPMorgan, Leerink Partners, Piper Sandler, and William Blair are the underwriters for this IPO.
